Form 4: Skye Bioscience Director Annalisa Jenkins Acquires Stock Options
SEC Form 4 Filing
Director Annalisa Jenkins acquired stock options in Skye Bioscience, Inc. on February 29, 2024.
Summary
- On February 29, 2024, Annalisa Jenkins, a director of Skye Bioscience, Inc., acquired 40,000 stock options.
- The options are exercisable at a price of $14.56 per share.
- The options vest in equal monthly installments over one year, starting February 29, 2024, and expire on March 1, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director, which can be interpreted as a sign of confidence, but doesn't provide enough information to be strongly positive.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of transaction: Annalisa Jenkins acquired stock options. |
| 02/29/2024 | Vesting start date: Options vest in equal monthly installments over one year. |
| 03/01/2034 | Expiration date: Stock options expire. |
| 03/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.